L- urtikarja, magħrufa b'mod komuni bħala l- ħruq, hija kundizzjoni tal- ġilda kkaratterizzata minn ħruq, ħruq imqajma li jistgħu jidhru fuq kwalunkwe parti tal- ġisem.
Din tistaʼ tiġi kkawżata minn diversi fatturi, inkluż reazzjonijiet allerġiċi, infezzjonijiet, jew kundizzjonijiet mediċi sottostanti.
It- trattament għall- urtikarja jiddependi fuq is- severità tal- kundizzjoni u l- kawża sottostanti.
Hawn huma xi għażliet komuni taʼ trattament:
1. Antihistaminiċi: Dawn il- mediċini jgħinu biex inaqqsu l- ħakk u l- nefħa billi jimblukkaw l- effetti tal- istamina, kimika rilaxxata mill- ġisem waqt reazzjoni allerġika.
L- antiistaminiċi over-the-counter bħal diphenhydramine (Benadryl) jew loratadine (Claritin) jistgħu jkunu effettivi f' każijiet ħfief.
F' każijiet aktar severi, it- tabib jista ' jippreskrivi antiistaminiċi aktar b' saħħa.
2. Kortikosterojdi: F' każijiet fejn l- antiistaminiċi ma jkunux effettivi, jistgħu jiġu preskritti kortikosterojdi bħal prednisone biex inaqqsu l- infjammazzjoni u jissuppressu s- sistema immunitarja.
Dawn il- mediċini ġeneralment jittieħdu mill- ħalq u jistgħu jipprovdu serħan mgħaġġel.
3. Immunosuppressanti: F' każijiet ta ' urtikarja kronika li ma jirrispondux għal trattamenti oħra, jistgħu jiġu preskritti mediċini immunosuppressanti bħal cyclosporine jew methotrexate biex jissuppressu s- sistema immunitarja u jnaqqsu l- infjammazzjoni.
4. Omalizumab: Dan il- mediċina hija antikorp monoklonali li jista ' jiġi injettat li jimmira u jimblokka l- immunoglobulin E (IgE), proteina involuta f' reazzjonijiet allerġiċi.
Tipikament jintuża għal urtikarja kronika li ma tirrispondix għal trattamenti oħra.
5. Evita l- fatturi li jikkawżaw l- urtikarja: L- identifikazzjoni u l- prevenzjoni tal- fatturi li jikkawżaw l- urtikarja jistgħu jgħinu fil- prevenzjoni tat- tifqigħa.
Il- fatturi komuni li jqanqlu dan jinkludu ċerti ikel, mediċini, biċċiet taʼ insetti, u espożizzjoni għas- sħana, is- kiesaħ, jew id- dawl tax- xemx.
6. Kompress bil- kiesaħ: L- applikazzjoni taʼ kompress bil- kiesaħ fuq il- post affettwat tistaʼ tgħin biex tnaqqas il- ħakk u l- nefħa.
7. Wraps imxarrba: Wraps imxarrba jistgħu jintużaw biex itaffu l- ħakk u jnaqqsu l- infjammazzjoni.
Ħwejjeġ imxarrba jiġu mdawra madwar il- post affettwat, u mbagħad jitqiegħdu ħwejjeġ niexfa fuqu biex iżommu l- umdità.
8. Fototerapija: L- esponiment għad- dawl ultraviolet jistaʼ jgħin biex jitrażżan is- sistema immunitarja u jnaqqas l- infjammazzjoni f'xi każijiet taʼ urtikarja kronika.
Huwa importanti li tikkonsulta professjonist tal- kura tas- saħħa għal dijanjosi u trattament xierqa ta ' l- urtikarja.
Huma jistgħu jgħinu biex jiddeterminaw il- kawża sottostanti u jirrakkomandaw l- iktar pjan taʼ trattament xieraq.
Deleanu D, Nedelea I, Petricau C, Leru P, Dumitrascu D, Muntean A: Clinical impact of omalizumab in refractory chronic urticaria: One centre experience. Exp Ther Med. 2019, 18 (6): 5078-5081.
Grundmann SA, Kiefer S, Luger TA, Brehler R: Delayed pressure urticaria - dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011, 9 (11): 908-12.
Staumont-Sallé D, Piette F, Delaporte E: [Etiological diagnosis and treatment of chronic urticaria]. Rev Med Interne. 2003, 24 (1): 34-44.
Akashi R, Ishiguro N, Shimizu S, Kawashima M: Clinical study of the relationship between Helicobacter pylori and chronic urticaria and prurigo chronica multiformis: effectiveness of eradication therapy for Helicobacter pylori. J Dermatol. 2011, 38 (8): 761-6.
Calogiuri G, Nettis E, Mandurino-Mirizzi A, Di Leo E, Macchia L, Foti C, Vacca A, Kounis NG: Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report. Antiinflamm Antiallergy Agents Med Chem. 2020, 19 (3): 335-339.
Tneħħija ta ' responsabbiltà: mediku
Dan is-sit tal-web huwa pprovdut għal skopijiet edukattivi u ta' informazzjoni biss u ma jikkostitwixxix l-għoti ta' parir mediku jew servizzi professjonali.
L- informazzjoni pprovduta m'għandhiex tintuża għad- dijanjosi jew it- trattament taʼ problema jew marda tas- saħħa, u dawk li jfittxu parir mediku personali għandhom jikkonsultaw maʼ tabib liċenzjat.
Jekk jogħġbok innota li n-netwerk newrali li jiġġenera t-tweġibiet għall-mistoqsijiet, huwa speċjalment mhux preċiż meta niġu għal kontenut numeriku. Pereżempju, in-numru ta' nies dijanjostikati b'marda speċifika.
Dejjem fittex il-parir tat-tabib tiegħek jew ta' fornitur tas-saħħa kwalifikat ieħor dwar kundizzjoni medika. Qatt ma tinjora l-parir mediku professjonali jew id-dewmien fit-tfittxija tiegħu minħabba xi ħaġa li qrajt f'dan il-websajt. Jekk taħseb li tista' jkollok emerġenza medika, ċempel 911 jew mur l-eqreb kamra tal-emerġenza immedjatament. L-ebda relazzjoni bejn tabib u pazjent ma tinħoloq minn dan il-websajt jew l-użu tagħha. La BioMedLib u lanqas l-impjegati tagħha, u lanqas kwalunkwe kontributur għal dan il-websajt, ma jagħmel xi rappreżentazzjonijiet, espressi jew impliċiti, fir-rigward tal-informazzjoni pprovduta hawnhekk jew għall-użu tagħha.
Riżerva ta' responsabbiltà: drittijiet tal-awtur
L-Att dwar id-Drittijiet tal-Awtur tal-Millennju Diġitali tal-1998, 17 U.S.C. § 512 (il-"DMCA") jipprovdi rikors għas-sidien tad-drittijiet tal-awtur li jemmnu li materjal li jidher fuq l-Internet jikser id-drittijiet tagħhom skont il-liġi tad-drittijiet tal-awtur tal-Istati Uniti.
Jekk temmen b'bona fidi li kwalunkwe kontenut jew materjal magħmul disponibbli b'rabta mal-websajt jew is-servizzi tagħna jikser id-drittijiet tal-awtur tiegħek, inti (jew l-aġent tiegħek) tista' tibgħatilna avviż li jitlob li l-kontenut jew il-materjal jitneħħa, jew li l-aċċess għalih jiġi mblukkat.
Id-DMCA teħtieġ li n-notifika tiegħek ta' ksur allegat tad-drittijiet tal-awtur tinkludi l-informazzjoni li ġejja: (1) deskrizzjoni tax-xogħol protett bid-drittijiet tal-awtur li huwa s-suġġett ta' ksur allegat; (2) deskrizzjoni tal-kontenut allegatament li jikser id-drittijiet tal-awtur u informazzjoni suffiċjenti biex inkunu nistgħu nsibu l-kontenut; (3) informazzjoni ta' kuntatt għalik, inkluż l-indirizz tiegħek, in-numru tat-telefon u l-indirizz tal-email; (4) dikjarazzjoni minnek li għandek twemmin ta' fidi tajba li l-kontenut bil-mod li dwaru l-ilment ġie ppreżentat mhuwiex awtorizzat mid-detentur tad-drittijiet tal-awtur, jew mill-aġent tiegħu, jew mill-operazzjoni ta' kwalunkwe liġi;
(5) stqarrija minnek, iffirmata taħt il-piena ta' perjuri, li l-informazzjoni fin-notifika hija preċiża u li għandek l-awtorità li tinforza d-drittijiet tal-awtur li huma ddikjarati li ġew miksura;
u (6) firma fiżika jew elettronika tas-sid tad-drittijiet tal-awtur jew ta' persuna awtorizzata li taġixxi f'isem is-sid tad-drittijiet tal-awtur.
In-nuqqas li tinkludi l-informazzjoni kollha ta' hawn fuq jista' jwassal għal dewmien fit-trattament tal-ilment tiegħek.
Kuntatt
Jekk jogħġbok ibgħatilna email b'kull mistoqsija / suġġeriment.
How to treat urticaria?
Urticaria, commonly known as hives, is a skin condition characterized by itchy, raised welts that can appear on any part of the body.
It can be caused by various factors, including allergic reactions, infections, or underlying medical conditions.
Treatment for urticaria depends on the severity of the condition and the underlying cause.
Here are some common treatment options:
1. Antihistamines: These medications help to reduce itching and swelling by blocking the effects of histamine, a chemical released by the body during an allergic reaction.
Over-the-counter antihistamines such as diphenhydramine (Benadryl) or loratadine (Claritin) can be effective in mild cases.
In more severe cases, a doctor may prescribe stronger antihistamines.
2. Corticosteroids: In cases where antihistamines are not effective, corticosteroids such as prednisone may be prescribed to reduce inflammation and suppress the immune system.
These medications are usually taken orally and can provide quick relief.
3. Immunosuppressants: In cases of chronic urticaria that do not respond to other treatments, immunosuppressant drugs such as cyclosporine or methotrexate may be prescribed to suppress the immune system and reduce inflammation.
4. Omalizumab: This medication is an injectable monoclonal antibody that targets and blocks immunoglobulin E (IgE), a protein involved in allergic reactions.
It is typically used for chronic urticaria that does not respond to other treatments.
5. Avoid triggers: Identifying and avoiding triggers that cause urticaria can help prevent outbreaks.
Common triggers include certain foods, medications, insect bites, and exposure to heat, cold, or sunlight.
6. Cold compress: Applying a cold compress to the affected area can help reduce itching and swelling.
7. Wet wraps: Wet wraps can be used to soothe itching and reduce inflammation.
A damp cloth is wrapped around the affected area, and then a dry cloth is placed over it to retain moisture.
8. Phototherapy: Exposure to ultraviolet light can help suppress the immune system and reduce inflammation in some cases of chronic urticaria.
It is important to consult a healthcare professional for proper diagnosis and treatment of urticaria.
They can help determine the underlying cause and recommend the most appropriate treatment plan.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Madwar
BioMedLib juża kompjuters awtomatizzati (algoritmi ta' tagħlim tal-magni) biex jiġġenera koppji ta' mistoqsijiet u tweġibiet.
Aħna nibdew b'35 miljun pubblikazzjoni bijomedika ta' PubMed/Medline. Ukoll, paġni tal-web ta' RefinedWeb.
